Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c

Fred Saad, Sebastien Hotte, Scott North, Bernie Eigl, Kim Chi, Piotr Czaykowski, Lori Wood, Michael Pollak, Scott Berry, Jean Baptiste Lattouf, Som D. Mukherjee, Martin Gleave, Eric Winquist

科研成果: 期刊稿件 › 文章 › 同行评审

116 引用 （Scopus）

指纹

探究 'Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c' 的科研主题。它们共同构成独一无二的指纹。

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science